trending Market Intelligence /marketintelligence/en/news-insights/trending/75x-AmOuP7zPA216dtDZLw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche exercises option to develop Ionis' drug for Huntington's disease

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Roche exercises option to develop Ionis' drug for Huntington's disease

Ionis Pharmaceuticals Inc. said Roche Holding AG exercised its option to license IONIS-HTTRx following the completion of a phase 1/2a study of the treatment in people with Huntington's disease.

Roche is taking over all development and commercial activities of the drug. Roche paid a $45 million license fee to Ionis for exercising the option. The transaction is subject to clearances under the Hart-Scott-Rodino Act.

IONIS-HTTRx is the first therapy in clinical development to target the underlying cause of Huntington's by reducing the production of the toxic mutant huntingtin protein. Huntington's disease is a rare genetic neurodegenerative disease resulting in deterioration in mental abilities and physical control. About 30,000 individuals in the U.S. have symptomatic Huntington's disease.

The safety and tolerability profile of the therapy observed in the study supports continued development. "For the first time, a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well tolerated," said Sarah Tabrizi, global lead investigator on the phase 1/2a study.